ライフサイエンスコーパス: light chain

1 riable genes and expression of the surrogate light chain.

2 core of an amyloidogenic immunoglobulin (Ig) light chain.

3 red by changes in the constant domain of the light chain.

4 oglobulin G gammopathy, 20 (58.8%) had kappa light chains.

5 ) coordinated by accessory proteins known as light chains.

6 on of eNOS(pThr497) and the 20 kDa myosin II light chains.

7 alently bonded factor VIII (FVIII) heavy and light chains.

8 lso circulate independently in blood as free light chains.

9 ogy in the variable domains of the heavy and light chains.

10 result of the selective decrease in kinesin light chain 1 expression.

11 I2 is the predominant involvement of the CDR light chain 1 in contrast to the commonly observed CDR h

12 pecies-specific peptides derived from myosin light chain-1 and 2 were identified for authenticating b

13 nary acetylcholine and phosphorylated myosin light chain 2 in bronchial smooth muscles.

14 lation of several proteins, including myosin light chain-2 slow and troponin T and carbonylation of m

15 ddition, increased phosphorylation of myosin light chain-20, a key regulator of lymphatic muscle cont

16 Beclin-1, and microtubule-associated protein light chain 3 (LC3) suggested autophagy in hippocampal c

17 were based on the accumulation of lipidated light chain 3 (LC3), an autophagosome marker, by Western

18 1 (SQSTM1), microtubule-associated protein 1 light chain 3 (LC3), gamma-aminobutyric acid receptor-as

19 Microtubule-associated protein 1 light chain 3 (LC3)-II protein levels were higher in HCM

20 marker microtubule-associated protein 1A/1B-light chain 3 (LC3).

21 ctivation of the primary autophagy effector, light chain 3 (LC3).

22 compartment evaluation, and western blotting light chain 3 (microtubule-associated protein 1A/1B-LC3)

23 dated form of microtubule-associated protein light chain 3 isoform B.

24 luding LC3 (microtubule-associated protein 1 light chain 3) (3,4) .

25 LC3-II (microtubule-associated protein 1A/1B-light chain 3) fractions, as well as fluorescence micros

26 re LC3 (microtubule-associated protein 1A/1B-light chain 3) is conjugated to phagosome membranes usin

27 onent LC3 (microtubule-associated proteins 1 light chain 3) to TLR-containing endosomes, which is ess

28 uch as LC3 (microtubule-associated protein 1 light chain 3), Beclin-1, and p62.

29 r producing microtubule-associated protein 1 light chain 3-II (LC3-II), which is required for autopha

30 induced lethality and inhibits activation of light chain 3.

31 cumulation of microtubule-associated protein light chain 3/lysosomal-associated membrane protein 2/p6

32 for a noncanonical form of autophagy called "Light-chain 3 (LC3)-associated phagocytosis" (LAP), lack

33 rked by the microtubule-associated-protein-1-light-chain-3 (LC3) conjugation system of autophagy and

34 y component microtubule-associated protein 1 light chain 3beta (Lc3b).

35 well as Retinitis Pigmentosa Type 2-Clathrin Light Chain, a membrane protein with a novel domain arch

36 Most renal amyloidosis cases are Ig light chain, AA, or leukocyte chemotactic factor 2 amylo

37 Thus, light chain accommodation of the glycan shield should be

38 (MM), Waldenstrom macroglobulinemia (WM) and light chain AL amyloidosis, are characterized by clonal

39 The management of light chain (AL) amyloidosis has improved in recent year

40 Systemic light chain (AL) amyloidosis is caused by the clonal pro

41 mide with dexamethasone for the treatment of light chain (AL) amyloidosis were to determine the safet

42 Among patients with immunoglobulin light chain (AL) amyloidosis, there is little consensus

43 In light of major advances in immunoglobulin light chain (AL) amyloidosis, we evaluated the trends in

44 Immunoglobulin M (IgM)-related light chain (AL) amyloidosis, which accounts for 6% to 1

45 le hematologic parameter in systemic amyloid light chain (AL) amyloidosis.

46 ents with relapsed/refractory immunoglobulin light chain (AL) amyloidosis.

47 ase controls (n = 20), and (5) patients with light-chain (AL) amyloid (n = 2).

48 Fifty patients with cardiac light-chain (AL) amyloidosis acted as disease comparator

49 alidated criteria of hematologic response in light-chain (AL) amyloidosis are based on the measuremen

50 tiparametric flow cytometry (MFC) in amyloid light-chain (AL) amyloidosis has not been widely adopted

51 dysfunction determines prognosis in amyloid light-chain (AL) amyloidosis.

52 Immunomodulatory drugs are active agents in light-chain (AL) amyloidosis.

53 .5+/-10.8 years, 65% male, 62.5% amyloidosis light chain [AL] type), 40 patients with hypertrophic ca

54 We tested whether light chain allelic inclusion occurs in circulating B ce

55 ich prevents dephosphorylation of the myosin light chain, allowing actomyosin contractility to procee

56 The majority of patients with immunoglobulin light chain amyloidosis (AL) fail to achieve a complete

57 dy aimed to assess the prognosis of systemic light chain amyloidosis (AL) patients treated with high-

58 tal secondary treatment strategy in systemic light chain amyloidosis (AL).

59 Light-chain amyloidosis (AL) with cardiac involvement ca

60 cytic malignancies, including immunoglobulin light-chain amyloidosis, multiple myeloma, and Waldenstr

61 patient with HCM due to superimposed amyloid light-chain amyloidosis.

62 ition and confirmed the diagnosis of amyloid light-chain amyloidosis.

63 trisulfide bonds was detected in between the light chain and heavy chain disulfide bond of the A and

64 d multiple myeloma cell growth, decreased Ig light chain and HSPA5/BIP expression, activated ERK and

65 and MYC and upregulated immunoglobulin (Ig) light chain and HSPA5/BIP Furthermore, pathway analysis

66 ICU admission day free light chain and immunoglobulin concentrations were signi

67 ed whether a concomitant abnormality in free light chain and immunoglobulin levels could identify a h

68 talytic subunit gamma isoform, neurofilament light chain and vesicular glutamate transporter 1.

69 a decrease in the levels of myosin heavy and light chains and caveolin-3.

70 Kappa and lambda light chains and IgH genes are main partners in a third

71 pointing to a toxic effect of amyloidogenic light chains and offering new potential therapeutic targ

72 Neurofilaments NF-L (neurofilament-light chain) and pNF-H (phosphorylated neurofilament-hea

73 binding sites for Munc13 and Tctex-1 (dynein light chain), and two C2-domains that bind to phospholip

74 seq, assembled the full-length heavy and the light chains, and experimentally confirmed these results

75 lymphocyte-activating molecule 7, and kappa light chain are under investigation as CAR targets.

76 Azi-iso identified myosin, actin, and myosin light chain as targets of the anesthetics.

77 F-actin, vinculin, and phosphorylated myosin light chain associated only with the peripheral assembli

78 d across species and suggest that the lambda light chain bias against HIV provides the host an advant

79 both light chains bound, consistent with the light chain-binding domain acting as a lever arm to ampl

80 Here we report that BoNT/A catalytic light chain binds to, and is a substrate for, the ubiqui

81 tubC, previously known as "bacterial kinesin light chain," binds along protofilaments every 8 nm, inh

82 RSV90 on RSV F, in which the heavy chain and light chain both have specific interactions mediating bi

83 ich PfMyoA moved actin was fastest with both light chains bound, consistent with the light chain-bind

84 Light chain cardiac amyloidosis, in particular, if recog

85 ss favorable interactions between the DRVIA7 light-chain CDR1 and the N terminus with N276 and V5 gly

86 analysis revealed a repertoire-encoded VRC01 light-chain CDR3 signature and VRC01-like neutralizing h

87 ncreasing its recognition of the Fab HM14c10 light chain CDRs.IMPORTANCE A chimeric yellow fever-deng

88 nt to the MTIP-binding site, and both myosin light chains co-located to the glideosome.

89 Phosphorylated myosin light chain colocalization with actin stress fibers incr

90 ies to rapidly remove nephrotoxic serum-free light chains combined with novel antimyeloma agents have

91 nbound RLC, but not excess unbound essential light chain, competes with liposome binding.

92 It is mostly light chain complementarity-determining regions that are

93 Although the importance of the MyoA-light chain complex is well-established, the detailed me

94 bjects and correlation assessed against free light chain concentrations.

95 ely; p = 0.0001); these correlated with free light chain concentrations.

96 e the complex nature of correlations between light-chain conformational flexibility, thermodynamic st

97 sed phosphorylation of the myosin regulatory light chain (cRLC) by the cardiac isoform of its specifi

98 kipping and synthesis of V domain-less kappa light chains (DeltaV-kappaLCs).

99 complex included GAP40, an additional myosin light chain designated essential light chain (ELC), and

100 estarting therapy, median difference of free light chain (dFLC) was 9.9 mg/dL (42% of diagnosis value

101 between involved minus uninvolved serum free light chains (dFLC) has been established as an invaluabl

102 ference between involved and uninvolved free light chains (dFLC) of >20 mg/L, a level >20% of baselin

103 CRBN, causing accumulation of immunoglobulin light-chain dimers, significantly increasing endoplasmic

104 This deubiquitinating enzyme binds BoNT/A light chain directly, with the two associating in cells

105 Interaction proteomics identified the dynein light chain DYNLL1 as interacting with RASGRP1, which li

106 able immunoglobulin domains of the heavy and light chain each providing three hypervariable loops, wh

107 able disease (measured by assessment of free light chains), Eastern Cooperative Oncology Group (ECOG)

108 ce lacking self-Thy-1 ligand, immunoglobulin light chain editing occurred, generating B cells with up

109 onal myosin light chain designated essential light chain (ELC), and several other candidate component

110 Nuclear factor kappa-light chain enhancer of activated B cells (NF-kappaB) is

111 rake on proinflammatory nuclear factor kappa light chain enhancer of activated B cells signaling in s

112 The nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) si

113 a negative regulator of nuclear factor kappa-light-chain enhancer of activated B-cells (NF-kappaB) si

114 onocytes have sustained nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) ac

115 tastasis-through a TLR4/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB)/si

116 -1alpha, that activated nuclear factor kappa-light-chain-enhancer of activated B cells (NFkappaB) and

117 ygen species [ROS]) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkappaB) in

118 NA expression levels of nuclear factor kappa-light-chain-enhancer of activated B cells and A20 were d

119 ulting in activation of nuclear factor kappa-light-chain-enhancer of activated B cells and increased

120 ated protein kinase and nuclear factor kappa-light-chain-enhancer of activated B cells and negative r

121 pacity to phosphorylate nuclear factor kappa-light-chain-enhancer of activated B cells in lymphoid ce

122 uced phosphorylation of nuclear factor kappa-light-chain-enhancer of activated B cells in stimulated

123 ated protein kinase and nuclear factor kappa-light-chain-enhancer of activated B cells were determine

124 able in phosphorylating nuclear factor kappa-light-chain-enhancer of activated B cells.

125 ignificant influence of nuclear factor kappa-light-chain-enhancer of activated B-cells on regulation

126 he transcription factor nuclear factor kappa-light-chain-enhancer, mitogen-activated protein kinase,

127 ht chains revealed that the presence of both light chains enhances MyoA-dependent actin motility.

128 However, the light chain evades proteasomal degradation by the domina

129 and raphe neurons in mice for tetanus toxin light chain expression, which prevented vesicular neurot

130 re of Tda2 revealed it belongs to the dynein light chain family.

131 based on the measurement of circulating free light chains (FLCs).

132 at require phosphorylation of the regulatory light chain for activation, phosphorylation of Rlc1 mark

133 erating bispecific antibodies using a common light chain format and exploiting the stable architectur

134 s impaired via conditional expression of the light chain from tetanus toxin (tox) in raphe neurons ex

135 bitor abrogated the release of the heavy and light chains from proCatC and blocked approximately 80%

136 ent subunit A (C1QA), FcgammaRIIIA, ferritin light chain (FTL), and solute carrier organic anion tran

137 mall, resting pre-B cells for immunoglobulin light chain gene rearrangement.

138 ons with the antigen, while for MAb 8E3, the light chain generally appears to make more contacts with

139 repertoire showed signs of convergent paired light-chain genetic signatures, including shared light-c

140 mutation in the human ventricular essential light chain (hVELC) of myosin, on the structural dynamic

141 and 3' RACE to clone and sequence heavy and light chain immunoglobulin mRNAs.

142 Serum total free light chain, immunoglobulin G, immunoglobulin A, and imm

143 nces for mRNAs encoding rearranged heavy and light chain immunoglobulins in B cells.

144 y independent relationship between high free light chain, immunoglobulins and hospital mortality.

145 cules to the N or C-terminus of the heavy or light chain in antibodies with excellent yields.

146 vector to specifically express tetanus toxin light chain in astrocytes) reduced the HVR in anaestheti

147 edge, abnormalities and associations of free light chain in critically ill adults with sepsis have no

148 ucible viral expression of the tetanus toxin light chain in male and female PV-Cre mice.

149 ting a viral vector expressing tetanus toxin light chain in male mice.

150 of a probe attached to the myosin regulatory light chain in skinned skeletal fibers, allowing us to p

151 in the thin filaments and myosin regulatory light chain in the thick filaments allowed us to identif

152 fluorescent probes on the myosin regulatory light chain in the thick filaments and on troponin C in

153 mately 10 kb downstream of myosin regulatory light chain interacting protein (MYLIP, aka IDOL and ind

154 he heavy chain overlaps with site O, and the light chain interacts partially with site II.

155 However, lacking the heavy-light chain interface of conventional antibodies, VHHs a

156 rotoxin (BoNT) binds to and internalizes its light chain into presynaptic compartments with exquisite

157 ing the peak areas from multiply charged mAb light chain ions using an in-house developed software pa

158 In neuronal cultures, BoNT/C1 ad light chain is rapidly internalized into presynaptic com

159 s suggests that conformational change of the light chain is rate-limiting for these proteins.

160 the targeted epitope, and that the maturated light chain is responsible for the improved affinity and

161 Two clathrin light chain isoforms, CLCa and CLCb, are integral compon

162 , high free light chain lambda and high free light chain kappa were seen in 46.5% and 75.3% of the st

163 Light chains kappa and lambda are immunoglobulin constit

164 nerated a CAR that is specific for the kappa light chain (kappa.CAR) and therefore recognizes kappa-r

165 -known, muscle-specific smooth muscle myosin light chain kinase (MLCK) (smMLCK) and skeletal muscle M

166 ities of Ca(2+) /calmodulin-dependent myosin light chain kinase (MLCK) and myosin light chain phospha

167 ) phosphorylation, which is driven by myosin light chain kinase (MLCK) and Rho-associated kinase (ROC

168 ARPC) subunit 2, 3, and 5, as well as myosin light chain kinase (MLCK) in these cells.

169 ACT: Ca(2+) /calmodulin activation of myosin light chain kinase (MLCK) initiates myosin regulatory li

170 Herein, we show that myosin light chain kinase (MLCK) plays a central role in the LP

171 arp2/3 and contractility regulated by myosin light chain kinase (MLCK) were responsible for the intri

172 ction (TJ) permeability by activating myosin light chain kinase (MLCK; official name MYLK3) gene.

173 cing, we found homozygous variants in myosin light chain kinase (MYLK) in both families.

174 Smooth muscle myosin light chain kinase (smMLCK) is a member of a diverse gro

175 lated by Ca(2+) /calmodulin-dependent myosin light chain kinase and dephosphorylated by myosin light

176 ities of Ca(2+) /calmodulin-dependent myosin light chain kinase and myosin light chain phosphatase (M

177 hrough two myosin-signaling pathways, myosin light chain kinase and Rho-associated kinase.

178 ng the stabilization of calmodulin by myosin light chain kinase at dramatically higher unfolding velo

179 Intestinal myosin light chain kinase expression decreased in Cd14-deficien

180 ytoskeletal defects, while inhibiting myosin light chain kinase or phosphorylation of focal adhesion

181 hosphorylation of myosin-bound RLC by myosin light chain kinase substantially inhibits binding to lip

182 xpressed specifically in the MHB, and myosin light chain kinase together mediate MHBC cell length.

183 analysis of tight junction proteins, myosin light chain kinase, and proinflammatory cytokine express

184 els are increased concomitantly with kinesin light chain (KLC-1/2) and immunoprecipitation and GST pu

185 that the protein abundance of the kinesin-1 light chain (KLC1) was reduced selectively in vivo and i

186 go along microtubules by one of many kinesin light chains (KLCs), which directly bind the cargo.

187 On ICU day 1, high free light chain lambda and high free light chain kappa were

188 The additional prognostic value of free light chain lambda and the significance of allelic inclu

189 HG1a), IgG2 (IGHG2), and IgA (IGHA), and the light chains (lambda and kappa).

190 e and rats of either sex, we show that MAP1B light chain (LC) accumulates in the somatodendritic comp

191 Systemic immunoglobulin light chain (LC) amyloidosis (AL) is a potentially fatal

192 of group 11 and 12 metals against the BoNT/A light chain (LC) protease.

193 nal production of an unstable immunoglobulin light chain (LC), which affects organ function systemica

194 ultiple myeloma (MM), soluble immunoglobulin light chains (LC) are produced by clonal plasma cells, b

195 phosphorylation of myosin 20-kDa regulatory light chains (LC20) but not of protein kinase C-potentia

196 Dynein light chain LC8 is highly conserved among eukaryotes and

197 In particular, abnormal Ig free light chains (LCs) may accumulate within epithelial cell

198 Compared to a homologous light-chain, LEN, which differs from SMA at eight positi

199 C472), and contained a stabilized heavy and light chain linkage (P221R mutation).

200 MLC-4, a nonmuscle myosin regulatory light chain, localizes to small punctate structures and

201 recombination machinery, the Ig heavy and Ig light chain loci rearrange in a stepwise manner.

202 that a microtubule-associated protein, MAP1B light chain (MAP1B-LC), participates in this process.

203 l proteins, microtubule-associated protein 1 light chain (MAP1LC3B) and Ras-like GTPase 11 (Rab11) we

204 nts to understand the contribution of doubly light chain mispaired bispecific IgG was demonstrated.

205 Myosin light chain (MLC) phosphorylation and MLC kinase (MLCK)

206 e first mapped the adjacent binding sites of light chains MLC1 and ELC1 on the MyoA neck (residues 77

207 (MM) patients expressing light chains only (light-chain MM [LCMM]) rely on measurements of monoclona

208 etion of LIMCH1 attenuated myosin regulatory light chain (MRLC) diphosphorylation in HeLa cells, whic

209 lation of their associated myosin regulatory light chains (MRLCs).

210 Different Guy's 13 antibody heavy and light chain mutant combinations were expressed transient

211 for parasite motility and includes the MyoA light chain myosin tail domain-interacting protein (MTIP

212 In addition to the known light chain myosin tail interacting protein (MTIP), we i

213 nvestigate canonical nuclear factor of kappa light chain (NF-kappaB) signaling in B cells from patien

214 the ability of CSF and plasma neurofilament light chain (NF-L) to predict and track clinical disease

215 arer definition of the role of neurofilament light chain (NFL) as a biomarker in amyotrophic lateral

216 As a marker of axonal damage, neurofilament light chain (NfL) has been suggested a marker for neurod

217 Neurofilament light chain (NfL) represents a promising biomarker for a

218 ects (n = 17) to CSF levels of neurofilament light chain (NFL), reflective of axonal damage and sCD27

219 the QAlb and the CSF level of neurofilament light chain (NFL), the ratio of N-acetylaspartate to cre

220 the neuronal damage biomarker, neurofilament light chain (NFL), were elevated compared to healthy don

221 Neurofilament light chains (NfL) are unique to neuronal cells, are she

222 he reagents were selective for the heavy and light chain of a monoclonal antibody, which when used co

223 ting proteins, including the heavy chain and light chain of an antibody Fab.

224 used to the N-terminus of the heavy chain or light chain of an antibody, either alone or in pairwise

225 ected by a reduction of exocytosis using the light chain of botulinum toxin C, nor by block of clathr

226 subunit (MYPT1) and the expression of myosin light chain of myosin II (MLC2), which was identified as

227 ction requires phosphorylation of the 20 kDa light chain of myosin, which activates crossbridge cycli

228 e immunized mice carrying both the heavy and light chains of gl3BNC60.

229 tif for subsequent cleavage to the heavy and light chains of mature MPO protomers, and (iii) three co

230 ng multiple myeloma (MM) patients expressing light chains only (light-chain MM [LCMM]) rely on measur

231 ed with changes in phosphorylation of myosin light chain or of myosin light chain phosphatase regulat

232 ores and high permeability to immunoglobulin light chains) or a conventional high-flux dialyzer (with

233 ification of designs that facilitate cognate light chain pairing may benefit from more refined method

234 g protein (MTIP), we identified an essential light chain (PfELC) that co-purified with PfMyoA isolate

235 t dephosphorylation for relaxation by myosin light chain phosphatase (MLCP) containing regulatory (MY

236 pendent myosin light chain kinase and myosin light chain phosphatase (MLCP), which contains a regulat

237 chain kinase and dephosphorylated by myosin light chain phosphatase (MLCP).

238 myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP).

239 sensitivity usually is attributed to myosin light chain phosphatase activity, but findings in non-VS

240 orylation of myosin light chain or of myosin light chain phosphatase regulatory subunit.

241 small phosphoprotein pCPI-17 inhibits myosin light-chain phosphatase (MLCP).

242 the leucine zipper (LZ) domain of the myosin light-chain phosphatase component, myosin-binding subuni

243 allow reevaluation of the role(s) of myosin light-chain phosphatase partner polypeptides in regulati

244 The extent of myosin regulatory light chain phosphorylation (RLC) necessary for smooth m

245 vates phospholipase Cbeta and induces myosin light chain phosphorylation to enhance actomyosin contra

246 alterations in calcium homeostasis or myosin light chain phosphorylation.

247 orylation at Ser-56 without affecting myosin light chain phosphorylation.

248 First, we highlight the impact of heavy and light chain phosphorylation.

249 uced RhoA GTP-loading and reversal of myosin light chain phosphorylation.

250 bilizing mutations is key for immunoglobulin light-chains populating unfolded intermediates that resu

251 We determine the role of one antigen-distal light chain position 83, demonstrating that mutation at

252 reprogramming of the muscle-specific myosin light chain promoter did occur.

253 through the C-terminal 77 amino acids of the light chain protease.

254 Light chain proximal tubulopathy (LCPT) is characterized

255 force microscopy, and phosphorylated myosin light chain quantity and actin fiber colocalization.

256 he understanding the various kappa to lambda light chain ratios observed across species and suggest t

257 tes expressed IgM heavy chains with Iglambda light chains, recapitulating the features seen in infect

258 Co-expression of MyoA with its two light chains revealed that the presence of both light ch

259 catalytic core that blocks myosin regulatory light chain (RLC) binding and phosphorylation in the abs

260 raction of the liposomes with the regulatory light chain (RLC) binding site in the myosin heavy chain

261 KEY POINTS: Smooth muscle myosin regulatory light chain (RLC) is phosphorylated by Ca(2+) /calmoduli

262 We show that depletion of myosin regulatory light chain (RLC) levels in the embryo blocks force gene

263 NM myosin regulatory light chain (RLC) phosphorylation but not SM myosin RLC

264 in kinase (MLCK) initiates myosin regulatory light chain (RLC) phosphorylation for smooth muscle cont

265 Regulatory light chain (RLC) phosphorylation has been shown to alte

266 e contraction initiated by myosin regulatory light chain (RLC) phosphorylation is dependent on the re

267 ess fibers (SFs) depend on myosin regulatory light chain (RLC) phosphorylation, which is driven by my

268 raction between kinase domain and regulatory light chain (RLC) substrate is identified in the absence

269 phosphorylation of the NM myosin regulatory light chain (RLC), NM myosin filament assembly and contr

270 eversed by phosphorylation of the regulatory light chain (RLC).

271 rylation of the myosin-associated regulatory light chain (RLC).

272 s/Sf9 insect cell system with its two native light chains, Rlc1 and Cdc4.

273 ective loss of p11 (also known as annexin II light chain, S100A10), a multifunctional protein binding

274 tebrate tropomyosin, arginine kinase, myosin light chain, sarcoplasmic calcium-binding protein, and h

275 s effects opposite to those of tetanus toxin light chain, separating the roles of ADL electrical and

276 task of assembling the full-length heavy and light chain sequences from single cell RNA-seq (scRNA-se

277 Alternatively, serum free light chain (sFLC) measurements have better sensitivity

278 achieve a complete response (CR) to standard light chain suppressive chemotherapy, and almost all pat

279 Silencing BPNs with tetanus toxin light chain (TeNT) increases bilateral masseter activati

280 ile fewer interactions are observed with its light chain than for the E protein.

281 t-chain genetic signatures, including shared light-chain third complementarity-determining region (CD

282 generation sequencing, to optimize heavy and light chains; this process yielded several improved vari

283 al B cells expressing the nontargeted lambda light chain, thus potentially minimizing humoral immunit

284 Preferential pairing of the anti-IL-13 light chain to its cognate heavy chain was observed, whi

285 ne defects and the measurement of serum free light chains to identify secondary hypogammaglobulinemia

286 In this report, we describe biased lambda light chain use during the HIV Env glycoprotein (Env) re

287 nding (and neutralization) in the context of light chain use in subjects with acute HIV infection, ch

288 function in a human infection being tied to light chain use.

289 antibody combining site involving heavy and light chain variable domains shaped by somatic hypermuta

290 was obtained for ongoing rearrangement of IG light chain variable genes and expression of the surroga

291 tease-like active site was identified in the light chain variable region of the antibody.

292 of a pathogenic kappa4 human immunoglobulin light-chain variable domain, SMA, associated with AL amy

293 y was to investigate the frequency of use of light-chain variable region (IGVL) genes among patients

294 We sequenced the paired heavy- and light-chain variable regions (VH and VL, respectively) f

295 d from the lymphoma immunoglobulin heavy- or light-chain variable regions.

296 ombinant antibodies with "matched" heavy and light chains were cloned as IgG1, and those of high affi

297 d IgM levels, as well as immunoglobulin free light chains, were measured in both patients with active

298 traction (via ROCK phosphorylation of myosin light chain), which are coupled to ECM signaling that is

299 ation is the long half-life of the catalytic light chain, which remains enzymatically active months a

300 to quantify any mAb in serum via the reduced light chain without the need for reagents specific for e

301 o an up-regulation of its substrate-specific light chain, xCT, and that this occurs, in part, at the